✨ Free AI Report
Olema Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Olema Pharmaceuticals, Inc.
Company Research

Olema Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of therapies for women's cancers. The company is advancing palazestrant, an estrogen re...

Analyst-debate audio for Olema Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Olema Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Well-positioned clinical-stage biotech with differentiated mechanism and bullish analyst consensus, pending Phase 3 trial...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics)
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Olema Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Olema Pharmaceuticals, Inc. Overview

Pro stress-test →

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of therapies for women's cancers. The company is advancing palazestrant, an estrogen receptor antagonist and selective ER degrader, through Phase 3 clinical trials for ER+/HER2- metastatic breast cancer. Strategic partnerships and multiple trial phases position Olema for potential FDA approval and market entry by 2027.

Strategic Profile

Pro stress-test →

Olema leverages advanced scientific methods to develop treatments addressing challenges of both wild-type and mutant estrogen receptor-positive diseases. Beyond palazestrant, the company is developing OP-3136, a KAT6 inhibitor being evaluated in combination with endocrine therapies to enhance anti-tumor efficacy. The company's precision medicine approach targets treatment resistance mechanisms in hormone-driven cancers.

Competitive Landscape

Pro stress-test →

Olema competes in the targeted oncology space against established players developing next-generation endocrine therapies for ER+ breast cancer. Competitors include large pharma companies with approved ER-targeted agents and other biotech firms in clinical development. Recent Roche Phase 3 results for giredestrant in early-stage breast cancer elevated competitive intensity, though Olema's dual-mechanism ER antagonist/degrader approach offers differentiation.

Industry Context

Olema Pharmaceuticals, Inc. operates in Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics).

Key facts

Founded: 2006 · Headquarters: San Francisco, California · Employees: 116 · Revenue: $0 · Market cap: $0.6B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Olema Pharmaceuticals, Inc..

  • Lead candidate palazestrant in pivotal Phase 3 OPERA-01 trial for second/third-line ER+/HER2- metastatic breast cancer with updated efficacy data supporting frontline combination studies
  • November 2025 public offering of $218.5M raised capital to fund ongoing Phase 3 trials and commercial preparations
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Closed $218.5M public stock offering to fund clinical development
  • November 2025Announced clinical trial agreement with Pfizer for palazestrant combination study
  • +2 moreTrack every material event for Olema Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Olema Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GiredestrantER antagonist in Phase 3 for early-stage breast cancer→Various CDK4/6 InhibitorsCombination partners and competitive alternatives in ER+/HER2- metastatic breast cancer→Next-generation Endocrine TherapiesClinical-stage and approved therapies for hormone receptor-positive breast cancer→

Compare Olema Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Olema Pharmaceuticals, Inc. operates in Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics) research →
NEW · MCP server

Ask your AI assistant about Olema Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Olema Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Olema Pharmaceuticals, Inc. do this quarter?”
“Is Olema Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Olema Pharmaceuticals, Inc. do?+
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of therapies for women's cancers. The company is advancing palazestrant, an estrogen re...
What is Olema Pharmaceuticals, Inc.'s Cyborg Score?+
Olema Pharmaceuticals, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Olema Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Giredestrant, Various CDK4/6 Inhibitors, Next-generation Endocrine Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Olema Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Olema Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Olema Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.